Sign In for increased benefits

Turn your one-off questions into a powerhouse research hub.

  • 🚨Real-time alerts on your custom watchlists
  • 🔍Unlock Deep Research Mode
  • 📊Exportable PDF/Word reports
  • 📚Revisit every question in your account history
  • ⭐Get personalised research and news based on your past questions
  • 🤝Team collaborate & annotate insights
  • 🌐Sync across devices—never lose your place
  • 👑Early-access to the next big AI features
  • 📚Continue enjoying 40 questions daily on your free account
About UsFAQsContact UsPrivacy PolicyCookies PolicyTerms and ConditionAcceptable Use PolicyData Processing Addendum
📢 New Earnings In! 🔍
Latest EarningsEarnings ChatEarnings FeedCompanies

Amylyx Pharmaceuticals, Inc.

AMLX

Healthcare
Biotechnology
US

Company Overview

Detailed information about Amylyx Pharmaceuticals, Inc.

Basic Information
Ticker: AMLX
Country: US
Headquarter: Cambridge, MA
Employees: 123
Financial Information
Market Cap: $658.8 Million
Currency: USD
Sector: Healthcare
Industry: Biotechnology

Stock Data provided by Financial Modeling Prep

Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Last Updated: Jul 2025

Here's what you can ask